AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $3.51 million. The enterprise value is $2.94 million.
Important Dates
The last earnings date was Tuesday, November 18, 2025, before market open.
| Earnings Date | Nov 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 2.86 million shares outstanding. The number of shares has increased by 102.28% in one year.
| Current Share Class | 2.86M |
| Shares Outstanding | 2.86M |
| Shares Change (YoY) | +102.28% |
| Shares Change (QoQ) | +175.71% |
| Owned by Insiders (%) | 3.72% |
| Owned by Institutions (%) | 4.94% |
| Float | 2.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.96 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64
| Current Ratio | 0.64 |
| Quick Ratio | 0.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -95.42% |
| Return on Invested Capital (ROIC) | -707.41% |
| Return on Capital Employed (ROCE) | -1,003.93% |
| Weighted Average Cost of Capital (WACC) | 14.39% |
| Revenue Per Employee | $4,870 |
| Profits Per Employee | -$684,783 |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.05% in the last 52 weeks. The beta is 1.24, so AIM ImmunoTech's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -93.05% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 4.14 |
| Relative Strength Index (RSI) | 50.27 |
| Average Volume (20 Days) | 3,228,181 |
Short Selling Information
The latest short interest is 61,954, so 2.17% of the outstanding shares have been sold short.
| Short Interest | 61,954 |
| Short Previous Month | 27,059 |
| Short % of Shares Out | 2.17% |
| Short % of Float | 2.25% |
| Short Ratio (days to cover) | 0.39 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $112,000 and -$15.75 million in losses. Loss per share was -$14.89.
| Revenue | 112,000 |
| Gross Profit | 17,000 |
| Operating Income | -14.57M |
| Pretax Income | -15.75M |
| Net Income | -15.75M |
| EBITDA | -14.34M |
| EBIT | -14.57M |
| Loss Per Share | -$14.89 |
Full Income StatementBalance Sheet
The company has $2.41 million in cash and $2.34 million in debt, with a net cash position of $71,000 or $0.02 per share.
| Cash & Cash Equivalents | 2.41M |
| Total Debt | 2.34M |
| Net Cash | 71,000 |
| Net Cash Per Share | $0.02 |
| Equity (Book Value) | -6.08M |
| Book Value Per Share | -2.20 |
| Working Capital | -1.47M |
Full Balance SheetCash Flow
| Operating Cash Flow | -12.93M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.93M |
| FCF Per Share | -$4.53 |
Full Cash Flow StatementMargins
| Gross Margin | 15.18% |
| Operating Margin | -13,006.25% |
| Pretax Margin | -14,062.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -102.28% |
| Shareholder Yield | -102.28% |
| Earnings Yield | -522.73% |
| FCF Yield | -429.00% |
Analyst Forecast
The average price target for AIM ImmunoTech is $21.98, which is 1,686.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.98 |
| Price Target Difference | 1,686.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 129.07% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 9, 2026. It was a forward split with a ratio of 1.001:1.
| Last Split Date | Jan 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.001:1 |
Scores
AIM ImmunoTech has an Altman Z-Score of -119.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -119.82 |
| Piotroski F-Score | 2 |
